SCHEMBL1999685

SCHEMBL1999685

OCc1csc(C(F)(F)F)n1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.35
ZAP70 P43403 3/20 0.35
SYK P43405 3/20 0.35
CDK2 P24941 2/20 0.35
SCD O00767 2/20 0.34
NUDT1 P36639 1/20 0.33
IDH1 O75874 2/20 0.33
GUCY1B2 O75343 1/20 0.32
GUCY1A2 P33402 1/20 0.32
GUCY1A1 Q02108 1/20 0.32
GUCY1B1 Q02153 1/20 0.32
MCHR1 Q99705 1/20 0.32
CCR1 P32246 1/20 0.31
AHR P35869 1/20 0.31
NOTUM Q6P988 1/20 0.31
LDHA P00338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9264985 0.84 NUDT1 (0.32) SRCZAP70SYKCDK2SCD
SCHEMBL16603243 0.80 F2RL3 (0.35) SRCZAP70SYKCDK2NUDT1
SCHEMBL1569158 0.79 IDH1 (0.33) IDH1MCHR1
SCHEMBL9045575 0.79 GFER (0.42) IDH1MCHR1
SCHEMBL12607354 0.79 IDH1 (0.33) IDH1MCHR1
SCHEMBL127293 0.79 IDH1 (0.33) IDH1MCHR1
SCHEMBL10223189 0.79 HRH1 (0.44) SRCZAP70SYKCDK2NUDT1
SCHEMBL5437866 0.79 IDH1 (0.36) IDH1MCHR1CCR1
SCHEMBL9262966 0.79 MCHR1 (0.34) IDH1MCHR1
SCHEMBL5329328 0.79 IDH1 (0.33) IDH1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2025-01-02 US disclosed
CN-108383858-B Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation 百时美施贵宝公司 2024-09-20 CN disclosed
US-12084452-B2 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation BRISTOL-MYERS SQUIBB COMPANY (US) 2024-09-10 US disclosed
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 CN disclosed
CN-117209449-A Synthesis method of 2- (trifluoromethyl) thiazole compound 上海毕得医药科技股份有限公司 2023-12-12 CN disclosed
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2023-08-03 US disclosed
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2023-08-03 US disclosed
EP-3632919-B1 PHARMACEUTICAL COMPOISITIONS COMPRISING IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2022-10-26 EP disclosed
WO-2021252849-A1 INHIBITORS OF APOL1 AND USE OF THE SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-16 WO disclosed
CN-112654621-A Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2021-04-13 CN disclosed
WO-2008027539-A1 INSECTICIDAL N-SUBSTITUTED (2- SUDSTITUTED-1,3-THIAZOL) ALKYL SULFOXIMINES DOW AGROSCIENCES LLC (US) 2008-03-06 WO disclosed
WO-2008027539-A1 INSECTICIDAL N-SUBSTITUTED (2- SUDSTITUTED-1,3-THIAZOL) ALKYL SULFOXIMINES DOW AGROSCIENCES LLC (US) 2008-03-06 WO disclosed
US-20080058394-A1 Insecticidal N-substituted (2-substituted-1,3-thiazol)alkyl sulfoximines DOW AGROSCIENCES LLC (US) 2008-03-06 US disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
EP-0728752-A1 Triazole compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-08-28 EP disclosed
US-5405861-A Fungicides TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) 1995-04-11 US disclosed
EP-0402246-B1 Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation ROUSSEL UCLAF (FR) 1994-08-24 EP disclosed
EP-0421210-A2 Triazole compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-04-10 EP disclosed
EP-0402246-A1 Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation ROUSSEL-UCLAF (FR) 1990-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058394-A1 Insecticidal N-substituted (2-substituted-1,3-thiazol)alkyl sulfoximines TST, NIT2, MSL1 SRC 2058/4885ZAP70 3103/4885SYK 1352/4885
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 SRC 318/4885ZAP70 2048/4885SYK 395/4885
US-12084452-B2 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation F2RL3, F2R, TMPRSS4 SRC 318/4885ZAP70 2048/4885SYK 395/4885
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 SRC 307/4885ZAP70 1977/4885SYK 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.